MeiraGTx HoldingsSTU:328 56 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates STU:328 with a GF Score™ of 56/100 and a GF Value™ of €20.56 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,196 Biotechnology companies, MeiraGTx Holdings ranks worse than 83611.96% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. MeiraGTx Holdings's annualized net income for the quarter that ended in Mar. 2026 was €-160.24 Mil. MeiraGTx Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €-28.08 Mil. Therefore, MeiraGTx Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.
The historical rank and industry rank for MeiraGTx Holdings's Return-on-Tangible-Equity or its related term are showing as below:
STU:328's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.305 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
MeiraGTx Holdings Return-on-Tangible-Equity Related Terms
MeiraGTx Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for MeiraGTx Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:328 vs XNCR, WVE, CGEM: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, MeiraGTx Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeiraGTx Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where MeiraGTx Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
MeiraGTx Holdings (STU:328) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MeiraGTx Holdings and its competitors. According to the industry distribution chart, MeiraGTx Holdings ranks #999999 out of 1196 companies in the Biotechnology industry.
Is MeiraGTx Holdings' Return-on-Tangible-Equity too high?
MeiraGTx Holdings' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, MeiraGTx Holdings ranks #999999 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Return-on-Tangible-Equity compare to XNCR and WVE?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #999999 out of 1196 companies for Return-on-Tangible-Equity. This places MeiraGTx Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (STU:328) is currently considered Possible Value Trap. The stock's GF Value™ is €20.56, compared to a current price of €12.10 — trading 41.1% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. MeiraGTx Holdings' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For MeiraGTx Holdings (STU:328), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeiraGTx Holdings (STU:328) Overvalued in 2026?
Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued.
The current stock price of €12.10 is trading 41.1% below its estimated GF Value™ of €20.56.
GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.
Key valuation signals for STU:328:
Return-on-Tangible-Equity: 0.00%
GF Value™: €20.56 vs. price of €12.10 (41.1% below fair value)
No single metric tells the full story. See the STU:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
56GF Score
Get the complete analysis for STU:328
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:328 has been successfully added to your 
